Valeant looks to buy back 2020 debt
US drug firm Valeant Pharmaceuticals International has started a cash tender offer for up to $1bn of three senior notes due 2020, with investors saying on Monday that the tender could prove so popular that there will be pressure to increase its size.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: